Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816295 · ClinicalTrials.gov registry record · Phase 3
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 715
- Enrollment target
NCT01816295 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 715 participants.
The verdict
NCT01816295, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 715 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate if testosterone solution can raise testosterone hormone levels into the normal range, and also improve levels of sexual arousal, interest and drive and/or energy level, in men with low testosterone and decreased sexual arousal, interest and drive and/or decreased energy. The study will last about 16 weeks, followed by an optional 24 week open label treatment phase to investigate the long term safety of testosterone solution.
Interventions
- DRUG Placebo Solution
- DRUG Testosterone Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 715 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01816295
The ClinicalTrials.gov registry entry for NCT01816295 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 715 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Solution is the first listed.
NCT01816295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01816295 about?
NCT01816295 is a clinical study titled "A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy". The main purpose of this study is to evaluate if testosterone solution can raise testosterone hormone levels into the normal range, and also improve levels of sexual arousal, interest and drive and/or energy level, in men with low testosterone and decreased sexual arousal, interest and drive and/or ...
What is the current status of trial NCT01816295?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 715 participants. The study started on 2013-05. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01816295?
The interventions under investigation include: Placebo Solution (DRUG), Testosterone Solution (DRUG).
Who is sponsoring clinical trial NCT01816295?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.